{"id":7570,"date":"2026-10-23T08:26:36","date_gmt":"2026-10-23T02:56:36","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/lupin-share-price-today-2026-10-23\/"},"modified":"2026-10-23T18:38:48","modified_gmt":"2026-10-23T13:08:48","slug":"lupin-share-price-today-2026-10-23","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/lupin-share-price-today-2026-10-23\/","title":{"rendered":"LUPIN Share Price Today: Why LUPIN Is Falling 0.01% | 23 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: LUPIN<\/strong> \u00b7 23 October 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b91,921.80<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>-0.01%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b91,929.90 \/ \u20b91,893.60<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b91,922.00<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>6.21 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>23 October 2026 \u00b7 03:00 PM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Lupin Limited shares traded in a relatively narrow band during the session on October 23, 2026, closing virtually flat with a minor change of -0.01% at \u20b91921.80 compared to the previous close of \u20b91922.00. The stock moved between an intraday high of \u20b91929.90 and a low of \u20b91893.60, touching its 52-week low level.<\/li>\n<li>Lupin Limited announced the appointment of Brian Savage as President, Chief Legal Officer, effective October 22, 2026. Savage will lead the company&#x27;s global Legal, Compliance, and Intellectual Property Management Group functions from New Jersey, bringing prior executive legal experience from Teva Pharmaceuticals. He holds a J.D. from Yale Law School and a B.A. from the University of Pennsylvania.<\/li>\n<li>Trading volume was 0.91 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is LUPIN share price falling on 23 October 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Lupin Limited shares traded in a relatively narrow band during the session on October 23, 2026, closing virtually flat with a minor change of -0.01% at \u20b91921.80 compared to the previous close of \u20b91922.00. The stock moved between an intraday high of \u20b91929.90 and a low of \u20b91893.60, touching its 52-week low level.<\/p>\n<p class=\"wt-copy\">The broader market and sector benchmarks experienced a downward pull during the trading day, with the Nifty index dropping 0.90% and the Nifty Pharma sector declining by 1.04%. Lupin&#x27;s modest price adjustment contrasted with the broader weakness seen across pharmaceutical peers, even as the stock extended its near-term correction, recording a 5-day return of -2.98% and a 20-day return of -8.61%.<\/p>\n<p class=\"wt-copy\">On the corporate front, Lupin announced the appointment of Brian Savage as President and Chief Legal Officer effective October 22, 2026, to oversee its global legal, compliance, and intellectual property functions from New Jersey. While this executive appointment highlights ongoing leadership additions following recent regulatory approvals and business updates, no direct causal link was established between the management announcement and today&#x27;s muted share price movement.<\/p>\n<p class=\"wt-copy\">6.21 lakh shares traded by 23 October 2026 \u00b7 03:00 PM IST. This compares with a 20-day average daily volume of 6.86 lakh shares (0.91 times). The five-day average daily volume was 6.73 lakh shares. Separately, the NSE report for 22 October 2026 showed 3.98 lakh shares delivered, representing 54.62% of that day\u2019s traded volume. The same report recorded 35,962 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>stock-specific consolidation amid sector weakness<\/strong><\/p>\n<p class=\"wt-copy\">Lupin&#x27;s share price closed flat with minimal change despite a declining broader market and pharmaceutical sector. The move reflects routine consolidation near its 52-week low without a confirmed single operational trigger driving today&#x27;s price action.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Brian Savage Appointed as President and Chief Legal Officer<\/div>\n<div class=\"wt-card-date\">23 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Lupin Limited announced the appointment of Brian Savage as President, Chief Legal Officer, effective October 22, 2026. Savage will lead the company&#x27;s global Legal, Compliance, and Intellectual Property Management Group functions from New Jersey, bringing prior executive legal experience from Teva Pharmaceuticals. He holds a J.D. from Yale Law School and a B.A. from the University of Pennsylvania.<\/p>\n<p class=\"wt-copy\">Strengthens executive leadership and governance capabilities overseeing complex global regulatory and intellectual property frameworks.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">U.S. FDA Approval for Phytonadione Injectable Emulsion<\/div>\n<div class=\"wt-card-date\">8 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Lupin received final approval from the U.S. Food and Drug Administration for its Phytonadione Injectable Emulsion, USP. The product approval expands the company&#x27;s injectable portfolio offering for the North American market. It reflects ongoing execution within its regulatory pipeline.<\/p>\n<p class=\"wt-copy\">Adds commercial depth and revenue visibility within the regulated U.S. generic injectables market.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Launch of Formoflo-G MDI for COPD Management<\/div>\n<div class=\"wt-card-date\">6 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company announced the launch of Formoflo-G MDI, positioned as the world&#x27;s first fixed-dose triple combination drug for Chronic Obstructive Pulmonary Disease management. The rollout targets respiratory care patients with an advanced therapeutic option. It expands Lupin&#x27;s specialty footprint in domestic and targeted markets.<\/p>\n<p class=\"wt-copy\">Enhances the respiratory therapy portfolio with an innovative combination product addressing chronic health conditions.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_06102026093541_SELetterpressrelease.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Press Release<\/div>\n<div class=\"wt-card-date\">23 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 23, 2026, titled &quot;Lupin Appoints Brian Savage as President, Chief Legal Officer&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_23102026095748_SELetterPressRelease.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Business update<\/div>\n<div class=\"wt-card-date\">9 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">a press release dated October 08, 2026, titled &quot;Lupin Receives U.S. FDA Approval for Phytonadione Injectable Emulsion, USP&quot;.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_08102026205937_SELetterPressRelease.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">46.84%<\/div>\n<div class=\"wt-note\">46.85% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">23.28%<\/div>\n<div class=\"wt-note\">22.42% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">47.06%<\/div>\n<div class=\"wt-note\">47.07% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1741171_19102026114146_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 14.58% on 30 September 2026. This compares with 14.84% on 30 June 2026, a change of -0.26 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 43 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">HDFC Mutual Fund-HDFC Arbitrage Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">2.14 crore shares \u00b7 4.68%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Nippon Life India Trustee Ltd- A\/C Nippon India Growth Mid Cap Fund<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.07 crore shares \u00b7 2.33%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mirae Asset BSE LARGEMID (60:40) Stable Dividend 50 ETF<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">85.86 lakh shares \u00b7 1.88%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1741171_19102026114146_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Historical Bulk \/ Block Deals<\/h2>\n<div class=\"wt-grid wt-grid-cards\">\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">Block<\/div>\n<div class=\"wt-card-date\">27 August 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal. Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal Moneycontrol.com<\/p>\n<div class=\"wt-note wt-source-note\">Moneycontrol.com<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Upcoming financial results for the quarter and half year ended September 30, 2026, scheduled for November 3, 2026<\/li>\n<li>Execution and market uptake of newly launched respiratory products such as Formoflo-G MDI<\/li>\n<li>Further commercialization progress regarding recent U.S. FDA approvals including Phytonadione Injectable Emulsion<\/li>\n<li>Delivery volume trends and cash participation around the 52-week low support zones<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/lupin-share-price-today-2026-10-22\/\">LUPIN Share Price Today: Why LUPIN Is Falling 2.14% | 22 October 2026 \u2014 22 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/lupin-share-price-today-2026-10-16\/\">Lupin in Focus Today Following Independent FY26 ESG Rating Assignment | 16 October 2026 \u2014 16 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/lupin-share-price-today-2026-10-08\/\">Lupin in Focus After Launching Formoflo-G MDI for COPD; What to Watch | 8 October 2026 \u2014 8 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/lupin\/\">More LUPIN news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest LUPIN company news?<\/h3>\n<p class=\"wt-copy\">Lupin Limited announced the appointment of Brian Savage as President, Chief Legal Officer, effective October 22, 2026. Savage will lead the company&#x27;s global Legal, Compliance, and Intellectual Property Management Group functions from New Jersey, bringing prior executive legal experience from Teva Pharmaceuticals. He holds a J.D. from Yale Law School and a B.A. from the University of Pennsylvania.<\/p>\n<h3>How strong was LUPIN\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">6.21 lakh shares traded, 0.91 times the 20-day average daily volume. The price and volume data are dated 23 October 2026 \u00b7 03:00 PM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/lupin-share-price-today-2026-10-23\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/lupin-share-price-today-2026-10-23\/\"}, \"headline\": \"LUPIN Share Price Today: Why LUPIN Is Falling 0.01% | 23 October 2026\", \"description\": \"LUPIN share price fell 0.01% to \u20b91,921.80 today. See why LUPIN is falling, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-10-23T02:56:36Z\", \"dateModified\": \"2026-10-23T18:38:39.879775+05:30\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"reviewedBy\": {\"@type\": \"Person\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/lupin-company-news-2026-10-23.jpg\"]}<\/script><!-- wt-article-record:{\"news_events\":[{\"title\":\"Press Release\",\"summary\":\"a press release dated October 23, 2026, titled \\\"Lupin Appoints Brian Savage as President, Chief Legal Officer\\\".\",\"source\":\"NSE\",\"published\":\"23-Oct-2026 10:00:22\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_23102026095748_SELetterPressRelease.pdf\",\"disclosure_text\":\"LUPIN LIMITED Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 info@lupin.com | www.lupin.com October 23, 2026 National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 BSE Limited P. J. Towers, Dalal Street, Mumbai Samachar Marg, Mumbai - 400 001 Symbol: LUPIN Scrip Code: Equity - 500257 Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 Dear Sir\/Madam, We are pleased to enclose a Press Release titled \u201cLupin Appoints Brian Savage as President, Chief Legal Officer\u201d. The same is for your information and dissemination. Thanking you, For LUPIN LIMITED AMIT KUMAR GUPTA COMPANY SECRETARY & COMPLIANCE OFFICER (ACS -15754) Encl.: a\/a. Page 1 of 1 BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN Press Release Lupin Appoints Brian Savage as President, Chief Legal Officer Mumbai, October 23, 2026: Global pharma major Lupin Limited (Lupin) announced the appointment of Brian Savage as President, Chief Legal Officer. Brian will lead Lupin\u2019s global Legal, Compliance, and Intellectual Property Management Group (IPMG) functions, and will be based in New Jersey. Brian joins Lupin from Teva Pharmaceuticals, where he held several senior leadership roles since 2015. Most recently, he served as Teva\u2019s Executive Vice President and Interim Global Chief Legal Officer. During his tenure, he also led Teva\u2019s global litigation strategy and served as General Counsel for its U.S. Generics business. Prior to joining Teva, Brian practiced law at Dechert LLP. Brian brings extensive experience navigating the complex legal and regulatory landscape in the global pharmaceutical industry. He holds a Juris Doctor (J.D.) from Yale Law School and a B.A., summa cum laude, from the University of Pennsylvania. Commenting on the appointment, Lupin CEO Vinita Gupta and Managing Director Nilesh Gupta said, \u201cWe are delighted to welcome Brian to our executive leadership team. His deep understanding of the pharmaceutical industry landscape, extensive legal expertise, and proven leadership will be valuable as we continue to strengthen our governance framework, navigate an evolving regulatory environment, and advance our long term growth ambitions.\u201d About Lupin Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 6 research centers globally, along with a dedicated workforce of over 26,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. To know more, visit www.lupin.com or follow us on LinkedIn https:\/\/www.linkedin.com\/company\/lupin For further information or queries, please contact: Rajalakshmi Azariah Vice President & Global Head \u2013 Corporate Communications, Lupin rajalakshmiazariah@lupin.com\"},{\"title\":\"Appointment\",\"summary\":\"the Appointment of a Senior Management Personnel.\",\"source\":\"NSE\",\"published\":\"22-Oct-2026 22:29:39\",\"source_type\":\"official filing\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_22102026222223_SE_Intimation_Appointment_of_Brian_Savage.pdf\",\"disclosure_text\":\"LUPIN LIMITED Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 info@lupin.com | www.lupin.com October 22, 2026 National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 BSE Limited P. J. Towers, Dalal Street, Mumbai Samachar Marg, Mumbai - 400 001 Symbol: LUPIN Scrip Code: Equity \u2013 500257 Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (\u2018SEBI Listing Regulations\u2019) \u2013 Appointment of Senior Management Personnel. Dear Sir\/Madam, We are pleased to inform the appointment of Mr. Brian Savage as a Senior Management Personnel, designated as President, Chief Legal Officer with effect from October 22, 2026. Mr. Savage will oversee the Company's Global Legal, Compliance and IP functions. The details required under Regulation 30 read with Schedule III of the SEBI Listing Regulations and the SEBI Master Circular dated January 30, 2026 (reference no. HO\/49\/14\/14(7)2025-CFD-POD2\/I\/3762\/2026), along with other applicable circulars (\u2018SEBI Master Circular\u2019), are set out in Annexure I. Kindly take the above on your records. Thanking you, For LUPIN LIMITED AMIT KUMAR GUPTA COMPANY SECRETARY AND COMPLIANCE OFFICER (ACS - 15754) LUPIN LIMITED Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 info@lupin.com | www.lupin.com Disclosure as per Regulation 30 of the SEBI Listing Regulations read with SEBI Master Circular. Appointment of Mr. Brian Savage as Senior Management Personnel designated as President, Chief Legal Officer. Sr. No. Particulars Details 1. Reason for Change viz. appointment, re-appointment, resignation, removal, death or otherwise Appointment of Mr. Brian Savage as Senior Management Personnel, designated as President, Chief Legal Officer. 2. Date of appointment\/ re-appointment October 22, 2026. 3. Term of appointment\/re-appointment; Full-time employment. 4. Brief Profile Mr. Brian Savage brings extensive legal leadership experience in the global pharmaceutical industry with deep expertise in legal and regulatory matters, litigation management and strategic business partnering. Before Lupin, he has worked with Teva Pharmaceuticals, where he held various senior leadership roles, most recently serving as Executive Vice President and Interim Global Chief Legal Officer. Prior to Teva, he practiced law at Dechert LLP. He holds a Juris Doctor (J.D.) degree from Yale Law School and a Bachelor of Arts degree from the University of Pennsylvania. As Chief Legal Officer, Mr. Brian Savage will oversee the Company's Global Legal, Compliance and IP functions. 5. Disclosure of relationship between Directors Not applicable.\"}],\"recent_news\":[{\"summary\":\"a press release dated October 08, 2026, titled \\\"Lupin Receives U.S. FDA Approval for Phytonadione Injectable Emulsion, USP\\\".\",\"category\":\"Press Release\",\"date\":\"08-Oct-2026 21:00:15\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_08102026205937_SELetterPressRelease.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"a press release dated October 06, 2026, titled \\\"Lupin Launches Formoflo-G\u00ae MDI, World s First Fixed-dose Triple Combination Drug for COPD Management\\\".\",\"category\":\"Press Release\",\"date\":\"06-Oct-2026 09:38:12\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_06102026093541_SELetterpressrelease.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":4},{\"summary\":\"a press release dated September 28, 2026, titled \\\"Lupin Receives Tentative Approval from U.S. FDA for Novel Apixaban Oral Suspension\\\".\",\"category\":\"Press Release\",\"date\":\"28-Sep-2026 09:13:36\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_28092026091311_SELetterPressRelease.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3},{\"summary\":\"a press release dated September 04, 2026, titled \\\"Lupin Receives U.S. FDA Approval for Modafinil Tablets, USP\\\".\",\"category\":\"Press Release\",\"date\":\"04-Sep-2026 17:38:35\",\"source\":\"NSE filing\",\"industry\":\"Pharmaceuticals\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/Lupin2_04092026173742_SELetterPressRelease.pdf\",\"headline\":\"Business update\",\"impact\":\"This is a substantive business update. Its relevance depends on whether it changes revenue growth, margins, capacity, competitive positioning or execution visibility.\",\"importance_score\":4,\"completeness_score\":3}],\"shareholding_snapshot\":{\"promoter_pct\":46.84,\"public_pct\":53.16,\"fii_pct\":23.28,\"dii_pct\":23.78,\"mf_pct\":14.58,\"institutional_pct\":47.06,\"noninst_pct\":6.09,\"mf_scheme_count\":43,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"HDFC Mutual Fund-HDFC Arbitrage Fund\",\"shares\":21400375,\"pct\":4.68},{\"name\":\"Nippon Life India Trustee Ltd- A\/C Nippon India Growth Mid Cap Fund\",\"shares\":10673280,\"pct\":2.33},{\"name\":\"Mirae Asset BSE LARGEMID (60:40) Stable Dividend 50 ETF\",\"shares\":8586274,\"pct\":1.88},{\"name\":\"Sbi Arbitrage Fund\",\"shares\":5146361,\"pct\":1.13}],\"period\":\"30-SEP-2026\",\"submission_date\":\"19-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1741171_19102026114146_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":46.85,\"previous_fii_pct\":22.42,\"previous_dii_pct\":24.65,\"previous_mf_pct\":14.84,\"previous_institutional_pct\":47.07,\"previous_mf_scheme_count\":39,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"bulk_block_deals\":[{\"deal_type\":\"Block\",\"date\":\"2026-08-27T07:00:00+00:00\",\"party\":\"\",\"side\":\"Sell\",\"quantity\":\"\",\"price\":\"\",\"summary\":\"Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal. Price Action | Lupin shares slip as Citi downgrades to sell; ICICI Pru AMC slips 3% on block deal Moneycontrol.com\",\"source\":\"Moneycontrol.com\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>LUPIN share price fell 0.01% to \u20b91,921.80 today. See why LUPIN is falling, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":7569,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"LUPIN Share Price Today: Why LUPIN Is Falling 0.01% | 23 October 2026","_witty_meta_description":"LUPIN share price fell 0.01% to \u20b91,921.80 today. See why LUPIN is falling, volume context, company developments and what to watch next.","_witty_primary_phrase":"LUPIN share price today","_witty_reason_label":"stock-specific consolidation amid sector weakness","_witty_reason_confidence":"low","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[222],"class_list":["post-7570","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-lupin"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/7570","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=7570"}],"version-history":[{"count":3,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/7570\/revisions"}],"predecessor-version":[{"id":8274,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/7570\/revisions\/8274"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/7569"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=7570"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=7570"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=7570"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}